Question 1

What is ipamorelin?

Accepted Answer

Ipamorelin is a laboratory-made peptide of five amino acids that prompts the pituitary gland to release growth hormone. The pituitary sits at the base of the brain and makes that hormone itself, so ipamorelin does not stand in for it. It asks for more of what is already there. The 1998 paper that introduced the compound describes a pentapeptide which displays high growth hormone releasing potency and efficacy in cells and in animals. It came out of a drug-discovery programme rather than out of nature. Ipamorelin was identified within a series of compounds lacking the central dipeptide of growth hormone-releasing peptide-1, and under its development code it appears as NNC 26-0161. A 2026 critical review sorts the field into classes and places it among the growth hormone secretagogues, a separate group from the CJC-1295 and sermorelin side of the family.

Question 2

Is ipamorelin a secretagogue?

Accepted Answer

Yes, and the word is carrying real weight. A secretagogue is something that makes a gland secrete what it already produces, rather than supplying that substance from outside. The 1998 paper calls ipamorelin the first selective growth hormone secretagogue, and a 2026 orthopaedic review groups it with CJC-1295, tesamorelin, sermorelin and AOD-9604 under that same heading. Selective is the part that distinguished it from everything before it. The older compounds in this family also pushed up the stress hormones, and ipamorelin reportedly did not. The 1998 work established the route using blocking agents, demonstrating that ipamorelin stimulates growth hormone release through a receptor shared with the earlier compound GHRP-6. So the door is the same one, and what came through it was narrower. A 2026 scoping review still lists ipamorelin among six emerging peptides examined for muscle and joint recovery, which is a long way from the purpose it was built for.

Question 3

Has ipamorelin been given to people?

Accepted Answer

Yes, which already separates it from most compounds sold this way. A 1999 study administered intravenous infusions to healthy male volunteers across five infusion rates, with eight healthy male subjects at each dose level, forty men in total. It measured concentrations of ipamorelin and growth hormone, and nothing else. A 2014 trial went further and asked whether the compound did anything useful, in patients recovering from bowel resection surgery. Two registered trials carry its name, one on postoperative ileus, which is the stall in bowel movement that follows abdominal surgery, and one on the recovery of gastrointestinal function. Both are listed as completed phase 2 studies. The published trial enrolled 117 patients, and the registry entry for the second lists 320. So a human record exists, it is roughly twenty-five years old, and every part of it concerns the gut or the bloodstream rather than muscle or appearance.

Question 4

What did the one controlled efficacy trial find?

Accepted Answer

It missed. The 2014 trial enrolled one hundred seventeen patients, of whom 114 made up the groups used for the safety and efficacy analysis, and it was a multicentre, double-blind, placebo-controlled clinical trial. Patients were given infusions of 0.03-mg/kg ipamorelin or placebo twice daily, from the first day after surgery to the seventh day or to discharge. The endpoint was how long it took before someone could eat a normal solid meal. Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, with a p value of 0.15. A seven-hour gap sounds like something. A p value of 0.15 means it sits inside what chance alone produces at that sample size. The authors concluded that there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.

Question 5

What was ipamorelin being developed for?

Accepted Answer

Not for physique. The 1998 paper closes by calling the specificity of ipamorelin a reason it is a very interesting candidate for future clinical development, and the development that followed went towards the gut. A 2012 rodent paper states the rationale plainly: delayed gastric emptying is a common disorder with few effective therapeutic options. Both registered trials and the published phase 2 concern postoperative ileus and the return of bowel function. After the 2014 trial missed its endpoint, nothing in the research behind this page records a further company trial. The second registered study is listed as completed, and no published report of it appears among these sources. Completed and published are different things, and the gap between them is where a programme usually stops.

Question 6

What did the animal work on the gut show?

Accepted Answer

Two rat experiments, both in a model of ileus produced by surgery. A 2009 study gave rats intravenous ipamorelin after abdominal surgery, then timed the first bowel movement. A single dose of 1 mg/kg decreased the time to the first bowel movement in those rats but had no effect on cumulative fecal output, food intake, or body weight gain at 48 hours. Repeated dosing did more. Dosing at 0.1 or 1 mg/kg significantly increased the fecal pellet output, the food intake and the body weight gain in the same rat model. A 2012 study examined the stomach instead and found that ipamorelin speeds up gastric emptying in a rat model of the same condition, by making the stomach contract harder. Both are rat results in animals immediately out of surgery, and the human version of that question was asked once and answered no.

Question 7

Does ipamorelin raise cortisol?

Accepted Answer

This is the finding the compound is known for. In the 1998 work, administration of the two older compounds in this family raised plasma levels of ACTH and cortisol in pigs, while ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following growth hormone-releasing hormone stimulation. ACTH is the message that instructs the adrenal glands to manufacture cortisol, the principal stress hormone. The separation held across a wide range: that lack of effect was evident even at doses more than 200 times the amount required for half the maximum growth hormone response. The same paper reported that none of the compounds tested affected four other pituitary outputs, including the two that govern the gonads. That is a real and specific pharmacological result, measured in pigs and rats, and it is not the same as a clean safety record.

Question 8

Will ipamorelin make me bigger?

Accepted Answer

No study among the research behind this page measured muscle size or strength in a person given ipamorelin. The nearest animal result is not about growth at all; it is about defending tissue under attack. A 2009 experiment gave rats prednisolone, a steroid that strips protein out of muscle and liver, and reported that the accelerated nitrogen wasting it caused was counteracted by either growth hormone or its secretagogue ipamorelin, though at the doses given less efficiently by the latter. Read the last clause. Growth hormone itself did the job better. A 2026 primer carries the only muscle-force result attached to ipamorelin, and it belongs to a pairing with CJC-1295 rather than to ipamorelin alone, so it is weighed on the page that covers that pairing. Protecting tissue a steroid is destroying and adding muscle to a healthy adult are different questions.

Question 9

Does ipamorelin mess with testosterone?

Accepted Answer

Not in any way measured in a man. The 1998 pig work recorded that none of the compounds tested affected the plasma levels of four other pituitary hormones, two of which drive the testes. The only experiment that looked directly at reproduction used fish. A 2024 study gave tilapia 5 or 30 micrograms of ipamorelin acetate for 21 days and saw a dose-dependent rise in food intake together with more sperm cells at several stages of development. In those same fish, serum luteinizing hormone and 11-ketotestosterone were significantly elevated against the control group, and 11-ketotestosterone is what stands in for testosterone in a fish. A result in tilapia does not carry across to a person. A 2020 review of this class in men with low testosterone reaches the general version of the point, finding that a paucity of data limits what can be said about any of them.

Question 10

How long does ipamorelin stay in the body?

Accepted Answer

Hours, and this is one of the few parameters established in people. The 1999 volunteer study reported a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady state of 0.22 L/kg. Half-life is the time it takes for the amount in the blood to fall by half. The hormone response was shorter still. The time course of growth hormone stimulation showed a single episode of release with a peak at 0.67 hours and an exponential decline to negligible concentration at all doses. One pulse, peaking around forty minutes, essentially finished after that. A 1998 rat study adds that ipamorelin was mainly excreted in the urine, whereas the related compound GHRP-6 was predominantly excreted in the bile. Those are measurements of how the body distributes and eliminates the molecule, rather than of anything it accomplishes.

Question 11

How was ipamorelin given in the published studies?

Accepted Answer

Into a vein, almost without exception. The 1999 volunteer study used infusions given over 15 minutes, and the 2014 trial used intravenous infusions twice daily for up to seven days. Both rat experiments used an intravenous bolus as well, so all of it is a hospital route, administered by staff who are watching. One route other than the vein has been measured, and it was measured in rats. A 1998 study reported that after intranasal application, the bioavailability of ipamorelin was estimated at approximately 20%, meaning the share of an amount that reaches the bloodstream. The same work noted that these peptides crossed the lining of the nose easily, and read that as promising for delivery. No study among the research behind this page gave ipamorelin under the skin, so every published figure belongs to a drip rather than to a syringe.

Question 12

What are the downsides of ipamorelin?

Accepted Answer

The honest answer has two halves: what the one trial recorded, and what the class carries. In the 2014 trial, the overall incidence of any treatment-emergent adverse events was 87.5% in the ipamorelin group and 94.8% in the placebo group. Nearly everyone in both arms experienced something, which is what happens after bowel surgery, and the two arms were close. The trial's conclusion covered 0.03-mg/kg twice daily for up to 7 days, which is one week, in hospital, under observation, and says nothing about months of use by a healthy adult. For the class, a 2026 scoping review records documented risks including cardiovascular complications and metabolic dysfunction such as insulin resistance. A 2026 review in Sports Medicine adds that rigorous human safety data are scarce, and there is potential for serious harm to patients.

Question 13

Is ipamorelin approved anywhere?

Accepted Answer

No regulator among the sources behind this page has approved ipamorelin for any indication. A 2026 review of peptides in ageing describes the split in this field. On one side it judged that approved medicines showed robust safety profiles from large trials, while the unapproved peptides showed promise before people and limited evidence in them, and still lack long-term safety data. Ipamorelin sits in the second group. A 2026 primer written for bone and joint doctors is blunter about what is missing, stating that the indications, dosing, frequency and duration of treatment all remain unknown. The only place ipamorelin appears in a United States regulatory record is the recall list, and that is a register of what was withdrawn rather than of what was allowed. Two completed phase 2 trials and no approval is a particular kind of history.

Question 14

Where does ipamorelin sit in drug-tested sport?

Accepted Answer

Less settled on this page than a reader might expect. A 2026 critical review names Ipamorelin first among the growth hormone secretagogues it covers, and records that regulatory bodies such as the World Anti-Doping Agency have responded by expanding detection technologies. The same review adds that outside elite sport nobody knows how widely compounds of this kind are used. None of the sources behind this page states whether ipamorelin itself is named on a prohibited list, so this page will not assert one either way. What that review does conclude is that peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic. The current prohibited list is published by each governing body, and it is the only document that settles the question for an athlete.

Question 15

What do the FDA recall records say about ipamorelin?

Accepted Answer

Ten Class II recalls name ipamorelin, and every one of them is about sterility rather than the molecule. The reasons on record are lack of assurance of sterility and lack of sterility assurance, repeated across five compounding firms between 2018 and 2021. The second pattern in the list is mixing. Five of the ten items were ipamorelin alone, one of them an Ipamorelin 3 mg Lyophilized 1 vial. The other five paired it with something else, including a CJC-1295 4MG/IPAMORELIN 4MG VIAL and an Ipamorelin+Sermorelin vial. A sterility failure is a finding about a filling line rather than about ipamorelin, and that is the useful way to read the list. What these records do establish is that compounded ipamorelin reached patients in the United States, and that batches of it were pulled back.

Question 16

How is ipamorelin thought to work?

Accepted Answer

Through the ghrelin receptor, which is the door hunger uses. Ghrelin is the hormone the stomach releases when it is empty, and it also triggers growth hormone release. A 2009 paper describes ipamorelin as a selective growth hormone secretagogue and agonist of the ghrelin receptor, agonist meaning something that switches a receptor on. The 1998 characterisation arrived at the same place from the pharmacology, concluding that ipamorelin is the first receptor agonist of its family with a selectivity for growth hormone release similar to that of the brain's own releasing hormone. That comparison is the whole claim: the same narrowness, by a different door. A 2026 orthopaedic review describes the downstream step, saying that secretagogues of this kind activate IGF-1 signaling and satellite cell repair, where IGF-1 is the growth factor the liver makes in response to growth hormone. The same review records a current lack of clinical trials behind that description.

Ipamorelin